The FDA’s Leucovorin Approval—A Departure From Evidentiary Standards

This Viewpoint explores the US Food and Drug Administration’s plan to approve leucovorin for patients with autism and the potential implications for evidentiary standards.

Corresponding Author: Daniel G. Aaron, MD, JD, S.J. Quinney College of Law, University of Utah, 383 S University St, Salt Lake City, UT 84112 (Daniel.Aaron@law.utah.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.